Group 1: Company Overview - Xian New Tong Pharmaceutical Research Co., Ltd. focuses on drug development for major liver diseases, including hepatitis B and liver cancer, with 8 core products in its pipeline [1] - Renben Co., Ltd. is the largest comprehensive bearing manufacturing group in China, with over 50,000 product specifications and a presence in over 70 countries [2] - Wolai Intelligent Technology Co., Ltd. specializes in smart manufacturing solutions for emerging industries, particularly in the automotive and semiconductor sectors [2] - Gaokai Technology is engaged in precision fluid control, with products used in semiconductor and consumer electronics industries [3] - Deep Blue Ocean Technology Co., Ltd. develops underwater robotics and solutions for various marine applications, holding 15 core technologies in the field [3] - Tongxin Medical Technology Co., Ltd. is an innovative medical device company focused on advanced heart failure treatments, with its first product approved in China and others in clinical trials [4] Group 2: Product Development and Market Position - New Tong Pharmaceutical has developed a first-class innovative drug, with one product already on the market and others in various clinical trial stages [1] - Renben has maintained the top position in domestic bearing production and sales for 12 consecutive years, nearing the capabilities of the top eight global competitors [2] - Wolai is recognized as a national key "little giant" enterprise, providing comprehensive smart manufacturing solutions [2] - Gaokai's product range includes flow control and precision dispensing systems, catering to the needs of intelligent manufacturing [3] - Deep Blue has established itself as a pioneer in the underwater robotics sector, with a complete product line and significant R&D investment [3] - Tongxin's CH-VAD system is the first fully magnetic levitation left ventricular assist device approved in China, with further innovations in the pipeline [4]

深圳商报·读创客户端记者 宁可坚 据上交所官网12月29日消息，新通药物IPO被受理，拟于上交所科创板上市，保荐机构为中信证券股份 有限公司。 根据招股书，新通药物是一家专注药物研发20余年的高新技术企业，聚焦于乙肝、代谢功能障碍相关脂 肪性肝炎及肝癌等重大肝病领域的药物开发，致力于研发具有自主知识产权、安全有效、以临床价值为 导向的创新药物，力求填补肝病领域未被满足的临床需求。 值得一提的是，这是新通药物第二次冲刺IPO。其曾经走完整个上市流程，距离上市成功仅差临门一 脚。 需要注意的是，新通药物透露，甲磺酸普雷福韦片采用独家代理经销模式进行销售，存在客户集中度较 高和独家代理商依赖的风险。 新通药物称，作为一家创新药研发的企业，公司现阶段将主要资源用于临床以及临床前阶段的研发活 动。目前，公司委托凯基信诚作为独家代理进行甲磺酸普雷福韦片的销售和市场推广。 2021年12月末，新通药物向上交所递交了科创板IPO申请，此后经过二轮问询后在2023年初顺利过会， 并于当年4月25日获得证监会注册生效批复。 但至此以后，新通药物的上市开始变得遥遥无期。IPO注册批复的有效期为12个月，这意味着新通药物 的注册批复 ...